Amarantus Bioscience Holdings Inc (AMBS)

[guardiangel]

To all who are open minded to connections..William Gartner wanted to reverse merge with Radient when he had control of ProvistaDX on July 2010..In July 2012 Will wanted to license our DR-70 reagent for his GCDX Lung Cancer test. During this time period, Ironridge dropped a law suit against Radient while GCDX and Will were in negotiations with Radient..Then Ironridge settled its law suit with Amarantus..It appears there was some sort of arrangement...imo Wolf

September 12, 2012 Ironridge drops law suit with Radient
November 9, 2012 Ironridge settles law suit with Amarantus.
December 14, 2012 Amarantus gets licensing rights from GCDX and MemoryDX entrepreneur William Gartner..


http://globalcancerdx.com/?reqp=1&reqr=nzcdYz5go3MvYzWyqN==

"September 4, 2012, the lawsuit Ironridge Global IV, Ltd. filed against us on December 8, 2010, in the Superior Court of California, Los Angeles County claiming breach of contract and seeking damages in excess of $30.0 million was dismissed by the Court, without prejudice, upon motion by the Plaintiff"

*****************************************************************

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8916229

Item 1.01 Entry into a Material Definitive Agreement


On 9 November 2012, Amarantus Biosciences, Inc. (the “Company”) entered into a Settle Agreement with Ironridge Global IV Ltd. whereby the Company settled accounts payable due Ironridge in the amount of $511,310.00 by issuing Ironridge 23 million shares of Company common stock.



The settlement, which was approved by the Court, provided for issuance of that number of Company common shares that would equal the debt amount plus eight (8%), plus attorney fees divided by eighty (80%) of the closing price of the Company’s commons stock on the day prior to the Court’s approval of the Settlement Agreement. If the number of shares required to be issued pursuant to the settlement calculation is more or less than 23 million shares, Ironridge must return shares or be entitled to receive more shares.

******************************************************************

http://www.sec.gov/Archives/edgar/data/838879/000114420412051872/v324024_8ka.htm

Section 1 - Registrant’s Business and Operations

Item 1.01 - Entry into Material Definitive Agreements



On July 17, 2012, we filed a Form 8-K to disclose a license agreement we entered into with Global Cancer Diagnostics, Inc. ("GCDx") in order to commercialize certain of our intellectual property in the form of a Lung Cancer test (the “Agreement”). Section 3.1 of the Agreement was amended on August 23, 2012 (the “Amendment”), with the remainder of the Agreement unchanged. Pursuant to the Amendment, GCDx will pay us an upfront license fee of $250,000 immediately upon receipt of funds from the first closing of its current financing for approximately $2,000,000, which was anticipated to close no later than September 15, 2012.



On September 14, 2012, we agreed to further amend Section 3.1 of the Agreement and replace it with the following:



“GCDx will pay a License Fee of Two Hundred and Eighty Thousand Dollars ($280,000) to RXPC immediately upon receipt of it funding in the amount of Two Million dollars, or on or before October 1, 2012. As of the date of this amendment, GCDx has paid a total of US$6,000 towards this licensing fee.”



Other than the above-mentioned change, the remainder of the Agreement remains unchanged and in full force. A copy of the Amendment dated September 14, 2012 is being filed as Exhibit 10.1 hereto.



Section 8 – Other Events

Item 8.01 – Other Events



On September 4, 2012, the lawsuit Ironridge Global IV, Ltd. filed against us on December 8, 2010, in the Superior Court of California, Los Angeles County claiming breach of contract and seeking damages in excess of $30.0 million was dismissed by the Court, without prejudice, upon motion by the Plaintiff.



Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits


Exhibit No. Description

10.1 Amendment to Agreement with Global Cancer Diagnostics, Inc. dated September 14, 2012

******************************************************************

http://www.fiercemedicaldevices.com/press-releases/amarantus-bioscience-licenses-lympro-alzheimers-disease-diagnostic-blood-te

UNNYVALE, Calif., Dec. 14, 2012 /PRNewswire/ – Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that it has licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, Inc. LymPro originated from the University of Leipzig in Germany and has received over $3 million in research grants from the National Institutes of Health (NIH).